Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.36 Analyst target: $7.50 Upside: 451.47%
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.